C oronary angioplasty using new devices has been targeted for patients in whom a suboptimal outcome might be expected using standard balloon methods."2 While new device angioplasty may be of particular benefit in certain lesion subsets, it is potentially associated with complications seen infrequently after standard angioplasty.1,3-6 One such event is the development of a major vascular complication, uncommon after balloon angioplasty but an important cause of periprocedural morbidity.7-13 Vascular complications may occur with greater frequency after new device angioplasty, theoretically due to the larger guiding catheters (directional and extraction atherectomy) and prolonged periods of anticoagulation (intracoronary stents) required by some of these devices.9 Moreover, blood loss requiring transfusions carries the attendant risk of disease transmission.
Prior studies have identified several clinical and procedural predictors for the development of vascular complications after standard balloon angioplasty.9,11
Notably, the prevalence of and predictive factors contributing to vascular complications after new device angioplasty have been incompletely defined. To Although the duration of heparin therapy was left to operator discretion within the parameters of new device protocol guidelines (Table 1) , a standard technique was generally used for sheath removal. Once heparin was discontinued, an ACT was measured 4 hours later and repeated hourly thereafter; once the ACT was <150 seconds, sheath removal was performed using manual compression. If heparin was readministered after sheath removal, a bolus of 2500 to 5000 U was given 2 to 4 hours after hemostasis was obtained, and an intravenous heparin infusion was reinstituted to maintain the activated partial thromboplastin time (aPTT) between 50 and 90 seconds (reference range, 25 to 35 seconds). In general, aPTTs were measured 4 hours after any heparin dose change and twice daily thereafter once a steady-state level of heparinization had been achieved. In patients undergoing intracoronary stent placement, intravenous dextran was also administered after the procedure and continued until the sheaths were removed, heparin restarted, and an aPTT >50 seconds was obtained. Oral dipyridamole (75 mg every 8 hours) was also given after the procedure in these patients.
The largest sheath size used for the procedure and the duration (in hours) that the sheath was in place were recorded. Use of intraprocedural thrombolytic agents (urokinase or tissue-type plasminogen activator) or intra-aortic balloon pump support also was noted. Hematocrit, platelet, and creatinine concentrations were recorded at baseline and obtained serially following the procedure; nadir hematocrit and platelet counts and maximum creatinine concentrations were recorded.
To determine the duration and intensity of anticoagulation after balloon and new device therapy, the use of postprocedural heparin for more than 6 hours after the procedure was recorded. The tomies, and 5 (3.2%) balloon and 3 (2.5%) laser angioplasty procedures. Major hematomas were the most frequent type of vascular complications, followed in frequency by formation of pseudoaneurysms, retroperitoneal hematomas, and arteriovenous fistulae. Surgical repair was required after 43 procedures (3.0%), including 11 (0.8%) patients who developed thromboembolism requiring embolectomy. Groin infections developed after 8 procedures (0.6%), 4 of which occurred after surgical correction of a vascular complication.
Predictors of Overall Vascular Complications
Several clinical and procedural predictors of overall vascular complications were identified using univariate logistic regression (Table 2) . Vascular complications were more common in older patients (P<.01), in those presenting with unstable angina (7.2% versus 3.9% in patients with stable angina; P<.05), and in those receiving procedural thrombolytic agents (20 (Fig 3) , it was not an important independent predictor using univariate or multivariate analysis. Other independent predictors of traumatic arterial injury included intracoronary stent use (P<.05), extraction atherectomy (P<.05), lower nadir platelet counts (P<.005), and recurrent ischemia (P<.01).
After uncomplicated coronary angioplasty, an average reduction in hematocrit of 6 
Study Limitations
This study has several important limitations. First, some major vascular complications, eg, the formation of pseudoaneurysms and arteriovenous fistulae, were identified by the use of vascular ultrasound or by direct inspection during surgical repair of an expanding hematoma. Early in the study period, duplex scanning was obtained only after the clinical suspicion of a major vascular complication was noted, eg, a large, pulsating hematoma, the presence of a pansystolic bruit, or a hematoma with continued blood loss. As the experience with duplex scanning increased, a lower threshold for using this important diagnostic tool developed, and smaller pseudoaneurysms and arteriovenous fistulae were identified; these were often amenable to direct compression, obviating the need for surgical repair. As a result, this study may underestimate the actual prevalence of vascular complications. Second, a number of predisposing clinical factors have been correlated with the development of vascular complications, some of which were not specifically examined in this study, such as body surface area and the number of hours of heparin administration. Finally, the anticoagulation regimens used after new device angioplasty in the present study were undergoing evolution during the study period. Based on the identification of the factors contributing to vascular complications, further alterations in coagulation regimens are ongoing; potentially lower rates of vascular complications may be expected.
Clinical Implications
The frequency of vascular complications identified in this study suggests that further efforts to reduce the vascular complication rates after balloon and new device angioplasty are needed. Due to the increased risk of vascular complications, intraprocedural thrombolytic agents should be administered judiciously, with their use based on the demonstrated need for local or systemic fibrinolysis and not simply as "insurance" against potential abrupt vessel closure. If anticoagulation with heparin is required by protocol design or due to a suboptimal device result, coagulation profiles should be monitored frequently and adjusted to maintain the aPTT at 1.5 to 2.0 times normal. Often, important time is lost in obtaining coagulation results due to laboratory receiving and processing delays. Bedside aPTT monitors may be important adjuncts to the monitoring of systemic anticoagulation after balloon and new device angioplasty. Newer direct groin compression devices may be used to facilitate periprocedural hemostasis after sheath removal. Finally, design changes implemented in those new devices requiring prolonged periods of anticoagulation, such as heparin bonding of intracoronary stents, will potentially render them less thrombogenic; these changes may allow shorter duration of heparin therapy after new device angioplasty and result in reductions in the overall incidence of
